NEWS & PUBLICATIONSFOLLOW THE EVIDENCE AS IT DEVELOPS.
Company milestones, competitive awards, peer-reviewed studies, and selected PDE4 research that informs the scientific thesis.
11H IN THE NEWS.
A clean, chronological newsroom with one featured milestone and short, scannable summaries.
COMPETITIVE RECOGNITION THAT MOVED THE PROGRAM FORWARD.
Use exact program names, years, award amounts, and recipient entities. Explain what each award funded.
2021NIH / NIDA SBIR
Substance use disorder
$350,000 Phase I award to support potency, specificity, safety, and tolerability studies.
2024NIH / NIDA
Addiction therapeutics
[INSERT VERIFIED AMOUNT] and program title; explain the experiment funded.
2024U.S. DEPARTMENT OF DEFENSE
Multiple sclerosis
[INSERT VERIFIED AMOUNT] and mechanism; explain the late-stage or neuroinflammation study objective.
[YEAR][ADDITIONAL RECOGNITION]
[AREA]
Include competitive programs, selected presentations, or formal recognitions only when publicly verifiable.
PUBLICATIONS ABOUT 11H.
Lead with the comprehensive pharmacology paper, then organize earlier medicinal chemistry and disease-model work by question answered.
FEATURED / OPEN ACCESS
PHARMACOLOGICAL CHARACTERIZATION AND PRECLINICAL EVALUATION OF 11H
Lackovic et al. | Frontiers in Pharmacology | Published January 8, 2026 | doi:10.3389/fphar.2025.1720327
FOUNDATIONAL CHEMISTRY
Vadukoot et al. (2020)
Discovery and early characterization of the 11h chemical series.
DISEASE-MODEL PAPERS
.
List papers in addiction, neuroinflammation, or other models only when 11h appears in the publication.
ABSTRACTS & POSTERS
ISAM and other meetings
Separate peer-reviewed manuscripts from conference abstracts and presentations.
SELECTED RESEARCH THAT EXPLAINS THE PDE4 OPPORTUNITY.
A curated reading list should support the thesis without looking like an indiscriminate bibliography.
01
TARGET BIOLOGY
PDE4, cAMP compartmentalization, immune regulation, and CREB-dependent neuronal signaling.
2–4 foundational reviews
02
CNS TRANSLATION
Brain penetration, target engagement, cognition, neurodegeneration, and neuroinflammation.
Prioritize human and translational work
03
CLASS TOLERABILITY
Nausea, emesis, dose limitation, subtype biology, and therapeutic-window strategies.
2–4 foundational reviewsMake the historical challenge explicit
04
CLINICAL VALIDATION
Approved peripheral PDE4 drugs and clinical studies of rolipram, roflumilast, ibudilast, and newer CNS programs.
2–4 foundational reviews